WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329480

CAS#: 92262-58-3

Description: Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.

Price and Availability


USD 650
USD 2250

USD 950
USD 3850

USD 1650
USD 5750

Valrocemide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329480
Name: Valrocemide
CAS#: 92262-58-3
Chemical Formula: C10H20N2O2
Exact Mass: 200.1525
Molecular Weight: 200.282
Elemental Analysis: C, 59.97; H, 10.07; N, 13.99; O, 15.98

Synonym: Valrocemide; TV-1901; TV 1901; TV1901; SPD-493; TVP-1901; SPD493; TVP1901; SPD 493; TVP 1901;. N-Valproyl glycinamide.

IUPAC/Chemical Name: N-(2-amino-2-oxoethyl)-2-propylpentanamide


InChi Code: InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Hovinga CA. Valrocemide (Teva/Acorda). Curr Opin Investig Drugs. 2004 Jan;5(1):101-6. Review. PubMed PMID: 14983982.

2: Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001 Jul;42(7):831-6. PubMed PMID: 11488880.

3: Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep. 2007 Jul-Aug;59(4):402-7. Erratum in: Pharmacol Rep. 2008 Mar-Apr;60(2):292. Galit, Shaltiel [corrected to Shaltiel, Galit]; Shirley, Mark [corrected to Mark, Shirley]; Ora, Kofman [corrected to Kofman, Ora]; Galila, Agam [corrected to Agam, Galila]. PubMed PMID: 17901568.

4: Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiełło M, Czuczwar SJ. New generation of valproic acid. Pol J Pharmacol. 2004 May-Jun;56(3):283-8. Review. PubMed PMID: 15215557.

5: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48. PubMed PMID: 15570674.

6: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002 Sep;51(1-2):31-71. PubMed PMID: 12350382.

7: Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. Review. PubMed PMID: 19443931.

8: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. doi: 10.1016/j.eplepsyres.2008.09.005. PubMed PMID: 19008076.

9: Hadad S, Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos. 1997 Oct;18(7):557-66. PubMed PMID: 9330777.

10: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 Jan;73(1):1-52. PubMed PMID: 17158031.

11: Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. Review. PubMed PMID: 16732716.

12: Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006 Jun;69(3):273-94. Review. PubMed PMID: 16621450; PubMed Central PMCID: PMC1562526.

13: Spiegelstein O, Yagen B, Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia. 1999 May;40(5):545-52. PubMed PMID: 10386522.

14: Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release. 1999 Nov 1;62(1-2):187-92. PubMed PMID: 10518650.

15: Hovinga CA. Novel anticonvulsant medications in development. Expert Opin Investig Drugs. 2002 Oct;11(10):1387-406. Review. PubMed PMID: 12387702.

16: Spiegelstein O, Bialer M, Yagen B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):195-200. PubMed PMID: 9367208.

17: Nicolson A, Leach JP. Future prospects for the drug treatment of epilepsy. CNS Drugs. 2001;15(12):955-68. Review. PubMed PMID: 11735615.

18: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58. PubMed PMID: 11137386.